Free Trial
NASDAQ:AURA

Aura Biosciences Q1 2025 Earnings Report

Aura Biosciences logo
$7.23 +0.29 (+4.18%)
Closing price 04:00 PM Eastern
Extended Trading
$7.21 -0.02 (-0.28%)
As of 06:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aura Biosciences EPS Results

Actual EPS
-$0.55
Consensus EPS
-$0.47
Beat/Miss
Missed by -$0.08
One Year Ago EPS
N/A

Aura Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Aura Biosciences Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Thursday, May 15, 2025
Conference Call Time
6:00AM ET

Upcoming Earnings

Aura Biosciences' Q3 2025 earnings is scheduled for Wednesday, August 13, 2025

Aura Biosciences Earnings Headlines

Aura Biosciences Posts Q2 Cash Surge
One stock to replace Nvidia
Investing Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another to rival Tesla… and a third to upset Nvidia. These little-known stocks are poised to overtake the three reigning tech darlings in a move that could completely reorder the top dogs of the stock market. Eric Fry gives away names, tickers and full analysis in this first-ever free broadcast.
See More Aura Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aura Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aura Biosciences and other key companies, straight to your email.

About Aura Biosciences

Aura Biosciences (NASDAQ:AURA), a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

View Aura Biosciences Profile

More Earnings Resources from MarketBeat